AstraZeneca Says Imfinzi Data Shows Improved Response in Gastric Cancers
June 02 2023 - 12:43PM
Dow Jones News
By Michael Susin
AstraZeneca said late Friday that interim analysis of the phase
III study regarding its Imfinzi drug together with chemotherapy
significantly improved pathologic complete response in gastric and
gastroesophageal junction cancers.
The Anglo-Swedish pharma giant said that the trial demonstrated
a statistically significant and clinically meaningful improvement
in the key secondary endpoint of pathologic complete response in
patients with resectable, early-stage and locally advanced gastric
and gastroesophageal junction cancers.
The company said that the trial will continue as planned to
assess overall survival data.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
June 02, 2023 12:28 ET (16:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From May 2023 to May 2024
